Skip to content

This is a promotional website fully funded and created by SERB Pharmaceuticals for UK Healthcare Professionals only.

United Kingdom

United States Germany

Report Adverse Event Here Prescribing Information Summary of Product Characteristics

HDMTX Use in Cancer Treatment
Mechanism of Action
- Voraxaze works in the circulation
- Voraxaze hydrolysis extracellular MTX
Efficacy & Safety
Dosing & Administration
- Posology
- Preparation & Administration
Resources

HDMTX Use in Cancer Treatment
Mechanism of Action
- Voraxaze works in the circulation
- Voraxaze hydrolysis extracellular MTX
Efficacy & Safety
Dosing & Administration
- Posology
- Preparation & Administration
Resources

You are viewing the Voraxaze▼(glucarpidase) website for the United Kingdom.

Certain BTG products may not be available within the chosen
location, and indications may differ from your country's approved use.

I am a patient

Continue

I am a Healthcare Professional

Outside of the UK

United States (EN) Germany (DE)

I am a Healthcare Professional
In the UK

UK-VRX-2600029 Date of Last Revision: February 2026

Paediatric population

The pooled clinical safety database for Voraxaze^®includes data for 232 patients up to 17 years of age¹

006165_Voraxaze_E_Detailer_09_AL_4

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Abbreviations: CIR, clinically important reduction;HPLC, high-performance liquid chromatography; MTX, methotrexate.

References

Summary of Product Characteristics (SmPC)^®.

UK-VRX-2600033 Date of Last Revision: February 2026

Marketing Authorization Holder: Protherics Medicines Development, Ltd

BTG is a registered trademark of BTG International Ltd.

SERB^® and the SERB logo are registered trademarks of SERB S.à.r.l.

Useful Links

About SERB Contact Us

Order Voraxaze

24x7 Medical Information

Other Links

Privacy Policy Customize Cookies Terms of Use

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard. or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to safety@serb.com

Ⓒ 2026 BTG International Inc. All rights reserved.
UK-VRX-2600029 Date of Last Revision: February 2026